期刊文献+

腋窝淋巴结阴性乳腺癌206例预后因素分析 被引量:3

Prognosis Analysis of Node-Negative Breast Cancer Patients Report of 206 Cases
暂未订购
导出
摘要 目的探讨腋窝淋巴结阴性乳腺癌的临床特点、治疗方法及预后的影响因素。方法收集206例腋窝淋巴结阴性乳腺癌患者的临床病理资料,应用Kaplan-Meier法计算生存率,应用log-rank检验各组生存率,采用COX比例风险模型进行多因素分析。结果全组患者5年无复发生存率为83.5%,总生存率为95.6%。单因素分析显示,年龄(P=0.0137)、肿块大小(P=0.0002)、术后放疗(P=0.0176)、化疗(P=0.0104)、内分泌治疗(P=0.0091)是影响淋巴结阴性乳腺癌患者5年无病生存的因素;年龄(P=0.0113)、肿块大小(P=0.0375)、ER(P=0.0046)、PR(P=0.0275)是影响淋巴结阴性乳腺癌患者5年总生存的因素。多因素分析显示,肿块大小(P=0.002)是影响淋巴结阴性乳腺癌患者5年无病生存的独立预后因素。结论肿块大小是影响淋巴结阴性乳腺癌患者5年无病生存的独立预后因素。 Objective This study was to investigate the clinical eharaetersties,effeetive treatment and prognosis in patients with early node-negative breast cancer. Methods The data of 206 node-negative breast cancer patients were retrospectively reviewed. The survival rate was calculated by Kaplan-Meier method and compared by log-rank test. COX multivariate prognosis analysis was performed. Results The 5-year disease-free survival rate of the 206 patients was 83.5 %, and the 5-year overall survival rate was 95.6%. Univariate analysis showed that age( P = 0, 0137 ), tumor size (P = 0. 0002 ), adjuvant radiotherapy (P = 0.0176), adjuvant chemotherapy ( P = 0.0104 ), adjuvant hormonal therapy were prognostic factors of early node-negative breast cancer in 5-year disease-free survival rate. Age( P = 0.0113 ) ,tumor size( P = 0.0375 ) ,expression of ER( P = 0. 0046 ) or PR( P = 0.0275 ) were prognostic factors of node-negative breast cancer in 5-year overall survival rate. Multivariate analysis showed that tumor size( P = 0. 002 ) was independent prognostic factors in 5-year disease-free survival rate. Conclusion The tumor size is independent prognostic factors of node-negative breast cancer in 5-year disease-free survival rate.
出处 《实用癌症杂志》 2007年第6期641-644,647,共5页 The Practical Journal of Cancer
关键词 乳腺癌 腋窝淋巴结 单因素分析 多因素分析 Breast cancer Node-negative Univariate analysis Multivariate analysis
  • 相关文献

参考文献9

  • 1Chung M, Chang HR, Bland KI, et al. Young women with breast carcinoma have a poorer prognosis than older women[J]. Cancer, 1996,77:97.
  • 2Chia SK, Speers CH, Bryce C J, et al. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies[ J]. J Clin Oncol,2004 ,22 : 1630.
  • 3Attiqa N. Mirza, MD, Nadeem Q, et al. Prognostic factors in node-negative breast cancer:a review of studies with sample size more than 200 and follow-up more than 5 years[J]. Ann Surg,2002,235 : 10.
  • 4Slamon D J, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. Science, 1987,235 (4785) : 177.
  • 5Ross JS, Fletcher JA. The HER2 oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy [J]. Stem Cells, 1998,16:413.
  • 6Tamoxifenfor early breast cancer:an overview of the randomised trials. Early breast cancer trialist's collaborative group [J]. Lancet,1998,351(9114) :1451.
  • 7Polychemotherapy for early breast cancer:an overview of the randomised trials. Early breast cancer tfialist's collaborative group[J]. Lancet, 1998,352 (9132) :930.
  • 8Fisher B, Jeong JH, Anderson S, et al. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from national surgical adjuvant breast and bowel project clinical trials [J].J Natl Cancer Inst,2004 ,96(24) :1823.
  • 9Hutchins L, Green S, Ravdin P, et al. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in lowrisk node-negative patients. First results of Intergroup Trial Int0102 [J].Proc Am Soc Clin Oncol, 1998,17 : 1a.

同被引文献27

  • 1Fisher ER,Costantino J,Fisher B,et al.Pathologicfindings from the national surgical adjuvant breastproject:discriminants for 15-year survival[J].Cancer,1993,71(6):2141-2150.
  • 2Kuru B.Prognostic significance of total number of nodesremoved,negative nodes removed,and ratio of positivenodes to removed nodes in node positive breast carcinoma[J].EJSO,2006,32(10):1082-1088.
  • 3Sosa JA,Diener-West M,Gusev Y,et al.Associationbetween extent of axillary lymph node dissection andsurvival in patients with stageⅠbreast cancer[J].AnnSurg Oncol,1998,5(2):140-149.
  • 4Moorman PG,Hamza A,Marks JP,et al.Prognosticsignificance of the number of lymph nodes examined inpatients with lynph node-negative breast caicinoma[J].Cancer,2001,91(12):2258-2262.
  • 5Weir L,Speers C,D'yachkova Y,et al.Prognosticsignificance of the number of axillary lynph nodesremoved in patients with node-negative breast cancer[J].J Clin Oncol,2002,20(7):1793-1799.
  • 6Van der Wal B,Butzelaar RM,van der Meij S,et al.Axillary lymph node ratio and total number of removedlymph nodes:predictors of survival in stageⅠandⅡbreastcancer[J].Eur J Surg Oncol,2002,28(5):481-489.
  • 7AL-Shibli KI,Mohammed HA,Mikalsen KS.Sentinellymph nodes and breast carcinoma:analysis of 70 cases byfrozen section[J].Ann Saudi Med,2005,25(2):111-114.
  • 8Querzoli P,Pedriali M,Rinaldi R,et al.Axillary lymphnode nanometastases are prognostic factors for metastaticrelapse in breast cancer patients[J].Clin Cancer Res,2006,15(12):6696-6701.
  • 9Cox CE,Kiluk JV,Riker AI,et al.Significance ofsentinel lymph node micrometastases in human breastcancer[J].J Am Coll Surg,2008,206(2):261-268.
  • 10de Boer M,van Deurzen CH,van Dijck JA,et al.Micrometastases or isolated tumor cells and the outcomeof breast cancer[J].N Engl J Med,2009,361(7):653-663.

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部